Avalyn Pharma Inc. Common Stock (AVLN) Comparison with companies in other sectors?

Avalyn Pharma Inc. Common Stock has a share price of 41.81M. You can analyze Avalyn Pharma Inc. Common Stock (AVLN) competitors across different market sectors through stock heatmaps.

What are AVLN's NET and operating margins?

Avalyn Pharma Inc. Common Stock (AVLN) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does AVLN's earnings per share (EPS) trend reflect its financial momentum?

Avalyn Pharma Inc. Common Stock (AVLN) EPS is -2.04 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Avalyn Pharma Inc. Common Stock is -13.20, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Avalyn Pharma Inc. Common Stock?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Avalyn Pharma Inc. Common Stock like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Avalyn Pharma Inc. Common Stock

AVLN•NASDAQ

Healthcare

Medical - Pharmaceuticals

$26.93

$-0.78(-2.81%)

U.S. Market is Open • 11:17

Avalyn Pharma Inc. Common Stock Fundamental Analysis

Avalyn Pharma Inc. Common Stock (AVLN) shows weak financial fundamentals with a PE ratio of -13.20, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze AVLN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze AVLN's fundamental strength across five key dimensions:

Efficiency Score

Weak

AVLN struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Moderate

AVLN shows balanced valuation metrics.

PE < 25

-13.20

PEG Ratio < 2

N/A

Growth Score

Weak

AVLN faces weak or negative growth trends.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

AVLN carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

AVLN struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is AVLN Expensive or Cheap?

P/E Ratio

AVLN trades at -13.20 times earnings. This suggests potential undervaluation.

-13.20

How Well Does AVLN Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How AVLN Stacks Against Its Sector Peers

Metric	AVLN Value	Sector Average	Performance
P/E Ratio	N/A	29.43	N/A
ROE	N/A	698.00%	N/A
Net Margin	N/A	-46280.00% (disorted)	N/A
Debt/Equity	N/A	0.42	N/A
Current Ratio	N/A	4.50	N/A
ROA	N/A	-14638.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Avalyn Pharma Inc. Common Stock's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Avalyn Pharma Inc. Common Stock Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is AVLN Expensive or Cheap?

How Well Does AVLN Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How AVLN Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Avalyn Pharma Inc. Common Stock (AVLN) Comparison with companies in other sectors?

What are AVLN's NET and operating margins?

In what way does AVLN's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Avalyn Pharma Inc. Common Stock?

How do I know if AAPL is overvalued or undervalued?